Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States

ABSTRACT: In 2015, the US Food and Drug Administration approved levodopa-carbidopa intestinal gel (LCIG; also known as carbidopa-levodopa enteral suspension in the US) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. LCIG provides a continuous infusion of levodo...

Descripción completa

Detalles Bibliográficos
Autores principales: Amjad, Fahd, Bhatti, Danish, Davis, Thomas L., Oguh, Odinachi, Pahwa, Rajesh, Kukreja, Pavnit, Zamudio, Jorge, Metman, Leonard Verhagen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822848/
https://www.ncbi.nlm.nih.gov/pubmed/31278691
http://dx.doi.org/10.1007/s12325-019-01014-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822848/
https://www.ncbi.nlm.nih.gov/pubmed/31278691
http://dx.doi.org/10.1007/s12325-019-01014-4

Ejemplares similares